Shamburg News · 8-K filed Nov 16, 2026, 4:00 PM EST
Insight Molecular Diagnostics Reports Third Quarter 2026 Results and Corporate Update
IMDX · Insight Molecular Diagnostics Inc.
- Earnings
- Other event
- Materiality: high
On November 16, 2026, Insight Molecular Diagnostics Inc. reported third quarter 2026 results, with revenue of $559,000 and a net loss of $3.6 million, or $0.10 per share, compared with a net loss of $10.9 million, or $0.34 per share, a year earlier. The results included a non-cash gain of $4.1 million from a change in the fair value of contingent consideration. The company also provided an update on the FDA review of its GraftAssureDx test, noting that its response to the agency's request for additional information is expected before the January 21, 2027 deadline.
Source: SEC EDGAR, Form 8-K, Items 2.02, 9.01, accession 0001493152-26-052323.
Written from the filing by Shamburg Markets. Figures are as reported by the company.